Somewhat Positive Press Coverage Somewhat Unlikely to Impact Alimera Sciences (NASDAQ:ALIM) Share Price
Media coverage about Alimera Sciences (NASDAQ:ALIM) has been trending somewhat positive on Monday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alimera Sciences earned a news impact score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.1428570865087 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern’s rankings:
- Can Alimera Sciences, Inc. (NASDAQ:ALIM) Grab Upward Traction … – FLBC News (flbcnews.com)
- Watching Historical Performance for Alimera Sciences, Inc. (NASDAQ:ALIM) – Jonesboro Recorder (jonesbororecorder.com)
- Alimera Sciences Announces Data to be Presented at the 2017 Annual ASRS Meeting – Nasdaq (nasdaq.com)
- Alimera Sciences’ CEO Dan Myers to Present US Real-World ILUVIEN® Post-Marketing Data During Ophthalmology … – Nasdaq (nasdaq.com)
Several equities research analysts have weighed in on the stock. Rodman & Renshaw assumed coverage on shares of Alimera Sciences in a report on Thursday, April 27th. They issued a “buy” rating and a $4.00 target price on the stock. HC Wainwright set a $5.00 target price on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Tuesday, July 11th. Zacks Investment Research upgraded shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. Cowen and Company reiterated a “buy” rating and issued a $3.00 target price on shares of Alimera Sciences in a report on Tuesday, July 11th. Finally, ValuEngine lowered shares of Alimera Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $3.38.
Alimera Sciences (ALIM) traded up 1.34% during midday trading on Monday, reaching $1.51. 37,804 shares of the company’s stock traded hands. Alimera Sciences has a 1-year low of $1.03 and a 1-year high of $1.77. The firm’s market cap is $98.88 million. The stock’s 50 day moving average price is $1.45 and its 200 day moving average price is $1.40.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $10.40 million during the quarter, compared to the consensus estimate of $10.20 million. During the same period in the prior year, the company posted ($0.17) earnings per share. The company’s revenue for the quarter was up 8.3% compared to the same quarter last year. Equities research analysts anticipate that Alimera Sciences will post ($0.21) EPS for the current year.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.